Abcuro Revenue and Competitors
Estimated Revenue & Valuation
- Abcuro's estimated annual revenue is currently $6.8M per year.
- Abcuro's estimated revenue per employee is $155,000
Employee Data
- Abcuro has 44 Employees.
- Abcuro grew their employee count by 29% last year.
Abcuro's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Technical Operations | Reveal Email/Phone |
3 | VP, Clinical Science | Reveal Email/Phone |
4 | VP Research, Head Data Management | Reveal Email/Phone |
5 | VP, Finance and Planning | Reveal Email/Phone |
6 | VP, Head Regulatory Affairs | Reveal Email/Phone |
7 | Director Analytical Development | Reveal Email/Phone |
8 | Associate Director, Financial Planning & Analysis | Reveal Email/Phone |
9 | Associate Director Clinical Operations | Reveal Email/Phone |
10 | Chief Medical Officer | Reveal Email/Phone |
Abcuro Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Abcuro?
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.
keywords:N/A
N/A
Total Funding
44
Number of Employees
$6.8M
Revenue (est)
29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.1M | 44 | 5% | N/A |
#2 | $9.5M | 44 | 7% | N/A |
#3 | $4.9M | 44 | -39% | N/A |
#4 | $15M | 44 | -43% | N/A |
#5 | $5.3M | 44 | 5% | N/A |